Bonus BioGroup
Press Room

Press Releases 2021

Press Releases 2021

As Covid-19 infections are rising and in light of significant improvements in the health and recovery of severe Covid-19 patients treated with MesenCure;
The Israeli Ministry of Health approved the joining of additional medical centers to the Phase II clinical trial for severe Covid-19 evaluating Bonus BioGroup's product MesenCure

In view of the spread of new variants of coronavirus, reduced vaccine effectiveness, and the imminent rise in Covid-19 incidence;
Bonus BioGroup demonstrated significant improvement in parameters indicating reduced tissue damage, including muscle tissue, in addition to alleviating pneumonia in severe Covid-19 patients treated with the advanced cell therapy product MesenCure

At the International Society for Cell & Gene Therapy (ISCT) 2021 annual meeting in New Orleans,
Bonus BioGroup presented complete success in treating COVID-19 patients with MesenCure, which significantly improved the patients’ health
The Israel Ministry of Health approved the phase II clinical trial for the treatment of life-threatening respiratory distress with Bonus BioGroup’s MesenCure therapy

Bonus BioGroup developed a network of artificial blood vessels, intended to enable better integration of transplanted lab-grown organs
A US granted patent provides Bonus BioGroup with exclusive rights for the development and marketing of its network of artificial blood vessels, which may become an essential component in tissue engineering

Following safety and efficacy preclinical results of the unique drug product MesenCure, a therapy specifically developed by Bonus BioGroup for the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia;


Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

Following a previous announcement, dated July 22, 2020 regarding the Company’s development of an advanced version of the drug product MesenCure, specifically developed to treat the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia, and subsequent to additional safety and efficacy preclinical results obtained, Bonus BioGroup is pleased to announce that on January 18, 2021, it has received the necessary approvals from the Israeli Ministry of Health and from Rambam Health Care Campus, Haifa, to conduct a phase I/II clinical trial to evaluate the safety and efficacy of MesenCure in the treatment of Covid-19 patients (hereinafter: “the clinical trial for the treatment of respiratory distress”).

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.